The Efficacy of Nanozyme in Neurodegenerative Diseases

Case ID:
C17516

Unmet Need

Oxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a cure.

 

 

Technology Overview

Disclosed herein are novel metal nanozymes to treat α-synucleinopathies. The reported compounds possess strong scavenging ability on oxidative stress, thereby blocking the aggregation of pathogenic prion-like α-syn and tau. Pre-clinical in vitro and in vivo proof of concept validated the strong ROS scavenging ability and inhibitory effect of the nanozymes on α-syn aggregation.

 

Stage of Development

In vitro and in vivo preclinical proof of concept.

 

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Nonozyme and use for treating Neurodegenerative Diseases ORD: Ordinary Utility China 202211378496.7   11/4/2022     Pending
EFFICACY OF NANOZYME IN NEURODEGENERATIVE DISEASES PCT: Patent Cooperation Treaty PCT PCT/US2023/078741   11/3/2023     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum